Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia

Post time 2021-10-18 17:18:14

journal:Molecular Cancer Therapeutics

Authors:Lu Zhang; Tianyu Cai; Xiaoyu Lin; Xiaoli Huang; Mai H. Bui; Joshua P. Plotnik; Richard J. Bellin; Emily J. Faivre; Vinitha M. Kuruvilla; Lloyd T. Lam; Xin Lu; Zheng Zha; Weiguo Feng; Paul Hessler; Tamar Uziel; Qi Zhang; Antonio Cavazos; Lina Han; Debra C. Ferguson; Gaurav Mehta; Sriram S. Shanmugavelandy; Terrance J. Magoc; Jenny Rowe; Neal C. Goodwin; Kathleen A. Dorritie; Michael Boyiadzis; Daniel H. Albert; Keith F. McDaniel; Warren M. Kati; Marina Konopleva; Yu Shen

Publication date:2021-10-

DOI：10.1158/1535-7163.mct-21-0029

Article link:http://dx.doi.org/10.1158/1535-7163.mct-21-0029

Article Source:American Association for Cancer Research (AACR)。

Remark:

Post time 2021-10-18 17:18:15

: This post has been completed
Completed attachments will be deleted within 24 hours.

Post time 2021-10-18 17:29:53

: This post has been completed
Completed attachments will be deleted within 24 hours.

Post time 2021-10-18 17:38:11

: This post has been completed
Completed attachments will be deleted within 24 hours.

[AACR] Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today